Stat3 Is a Potential Target for Malignant Pleural Mesothelioma (MPM) Treatment

被引：0
|
作者：
Matsumoto, Seiji [1 ]
Nakamichi, Tohoru [1 ]
Kuroda, Ayumi [1 ]
Hashimoto, Masaki [1 ]
Takuwa, Teruhisa [1 ]
Kondo, Nobuyuki [1 ]
Hasegawa, Seiki [1 ]
机构：
[1] Hyogo Coll Med, Thorac Surg, Nishinomiya, Hyogo 6638501, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Mesothelioma; STAT3;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.08-002
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [1] A combination of Stat3 inhibitor and radiation for the treatment of malignant pleural mesothelioma
    Matsumoto, Seiji
    Doi, Hiroshi
    Fukuda, Akihiro
    Nakamichi, Tohoru
    Kuroda, Ayumi
    Hashimoto, Masaki
    Takuwa, Teruhisa
    Kondo, Nobuyuki
    Hasegawa, Seiki
    CANCER RESEARCH, 2017, 77
  • [2] Combined modality treatment for malignant pleural mesothelioma (MPM)
    Nafteux, Ph.
    Nackaerts, K.
    Lievens, Y.
    Vansteenkiste, J.
    Demedts, M.
    Van den Bogaert, W.
    Lerut, T.
    LUNG CANCER, 2006, 52 : S26 - S26
  • [3] Combined modality treatment for Malignant Pleural Mesothelioma (MPM)
    Nackaerts, Kristiaan
    Nafteux, Philippe
    Lievens, Yolande
    Vansteenkiste, Johan
    Demedts, Maurits
    van den Bogaert, Walter
    Lerut, Toni
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S429 - S429
  • [4] Pemetrexed and carboplatin in the treatment of malignant pleural mesothelioma (MPM)
    Papi, M.
    Genestreti, G.
    Tassinari, D.
    Tamburini, E.
    Nicoletti, S.
    Nicolini, M.
    Fabbri, P.
    Fabbri, P.
    Santo, A.
    Pasquini, E.
    Ravaioli, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Diagnostic potential of microRNAs (miRs) in malignant pleural mesothelioma (MPM).
    Andersen, Morten
    Grauslund, Morten
    Ravn, Jesper
    Sorensen, Jens B.
    Andersen, Claus B.
    Santoni-Rugiu, Eric
    CANCER RESEARCH, 2013, 73 (08)
  • [6] Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
    Lapidot, Moshe
    Case, Abigail E.
    Larios, Dalia
    Gandler, Helen I.
    Meng, Chengcheng
    Tosic, Isidora
    Weisberg, Ellen L.
    Poitras, Michael J.
    Gokhale, Prafulla C.
    Paweletz, Cloud P.
    Podar, Klaus
    Salgia, Ravi
    Saladi, Srinivas V.
    Griffin, James D.
    Frank, David A.
    Bueno, Raphael
    Sattler, Martin
    CANCERS, 2021, 13 (01) : 1 - 15
  • [7] Influence of a STAT3 inhibitor on tumor infiltrating lymphocytes in malignant pleural mesothelioma
    Matsumoto, Seiji
    Takuwa, Teruhisa
    Kondo, Nobuyuk
    Hasegawa, Seiki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] ASSESSMENT OF CIRCULATING MIRNAS AS POTENTIAL BIOMARKERS FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Kirschner, M. B.
    Cheng, Y. Y.
    Badrian, B.
    Creaney, J.
    Edelman, J. J.
    Musk, A. W.
    Robinson, B. W.
    Klebe, S.
    van Zandwijk, N.
    Reid, G.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S83 - S83
  • [9] Dysphagia in Patients with Malignant Pleural Mesothelioma (MPM)
    Malec, M.
    Desai, A.
    Waxman, I.
    Karrison, T.
    Rose, B.
    Mendoza, A.
    Gadiraju, M.
    Straus, C.
    Churpek, J.
    Kindler, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S759 - S760
  • [10] Malignant pleural mesothelioma (MPM) -: the Italian experience
    Crinó, L
    Benedetti, G
    LUNG CANCER, 2004, 45 : S137 - S138
12345